Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label trial of clofarabine and temsirolimus in older patients with relapsed or refractory AML
2007-005374-31Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Mar 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine and temsirolimus in acute myeloid leukemia (AML), sponsored by GIMEMA. Primary endpoint: Complete remission rate (CR + CRi). Started Mar 2009; status: completed.
02
Drugs
clofarabinetemsirolimus
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-005374-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005374-31.